Table 3.
Statistical Summary of Treatment Comparisons for Ertugliflozin, Sitagliptin, Metformin, Glimepiride, and Simvastatin
| GMR (90% CI) | ||||
|---|---|---|---|---|
| Analyte | Test | Reference | AUCinf | Cmax |
| Ertugliflozin‐Sitagliptin Study | ||||
| Ertugliflozin | Ertugliflozin + Sitagliptin | Ertugliflozin | 102.3 (99.7, 104.9) | 98.2 (91.2, 105.7) |
| Sitagliptin | Ertugliflozin + Sitagliptin | Sitagliptin | 101.7 (98.4, 105.0) | 101.7 (91.7, 112.8) |
| Ertugliflozin‐Metformin Study | ||||
| Ertugliflozin | Ertugliflozin + Metformin | Ertugliflozin | 100.3 (97.4, 103.3) | 97.1 (88.8, 106.3) |
| Metformin | Ertugliflozin + Metformin | Metformin | 100.9 (90.6, 112.4) | 94.0 (82.9, 106.6) |
| Ertugliflozin‐Glimepiride Study | ||||
| Ertugliflozin | Ertugliflozin + Glimepiride | Ertugliflozin | 102.1 (97.2, 107.3) | 98.2 (92.2, 104.6) |
| Glimepiride | Ertugliflozin + Glimepiride | Glimepiride | 109.8 (98.1, 122.9) | 97.4 (71.1, 133.5) |
| Ertugliflozin–Simvastatin Study | ||||
| Ertugliflozin | Ertugliflozin + Simvastatin | Ertugliflozin | 102.4 (99.6, 105.3) | 105.2 (98.3, 112.5) |
| Simvastatin | Ertugliflozin + Simvastatin | Simvastatin | 123.8 (90.9, 168.7) | 119.1 (97.2, 145.8) |
| Simvastatin Acid | Ertugliflozin + Simvastatin | Simvastatin | 130.5 (108.3, 157.1) | 115.7 (95.7, 139.7) |
AUCinf, area under the plasma concentration–time profile from time 0 extrapolated to infinite time; CI, confidence interval; Cmax, maximum observed plasma concentration; GMR, geometric mean ratio.